Latest Headlines

  1. Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval For Segmented Production 7/8/2026

    Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive inspection from three provincial regulatory bodies in China.

  2. Saol Therapeutics Resubmits The New Drug Application For SL1009 (DCA) For The Treatment Of Pyruvate Dehydrogenase Complex Deficiency (PDCD), An Ultra-Rare Disease 7/7/2026

    Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009, sodium dichloroacetate (DCA), for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), a rare, life-threatening mitochondrial disease with no FDA-approved therapies.

  3. Altasciences And Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough 7/7/2026

    Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025.

  4. Certara Accelerates Drug Discovery And Development With NVIDIA BioNeMo Agent Toolkit 7/7/2026

    Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.

  5. Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery With Broad Analysis And International AI Initiative 7/7/2026

    Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, has recently reported that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX Bio”), successfully completed a broad analysis of SLC transport proteins and initiated an international AI drug discovery initiative with Boltz, PBC (“Boltz”), to accelerate the discovery of novel small-molecule modulators of these targets.

  6. The University Of Colorado Anschutz, Along With UCHealth And Children's Hospital Colorado, Form Strategic Alliance With Bayer To Advance Drug Development And Clinical Trials 7/7/2026

    Bayer, a global life sciences company, has announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children's Hospital Colorado, establishing Bayer's first alliance of its kind with an academic medical center.

  7. Helix Announces Multi-Year Agreement With AstraZeneca To Support Genomic Research For Drug Discovery And Development 7/7/2026

    Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company.

  8. Aureka Releases OpenDDE, An Open-Source Drug Discovery Engine Designed To Accelerate AI-Driven Therapeutic Discovery 7/6/2026

    Aureka, an AI TechBio company building infrastructure for AI-driven biologics discovery, today announced the release of Open Drug Discovery Engine (OpenDDE), an open-source, all-atom biomolecular foundation model designed to serve as the structural reasoning core of next-generation drug discovery systems.

  9. Ascletis Submits Two IND Applications To The U.S. FDA For The Treatment Of Obesity: ASC36 Once-Monthly Injection, A Peptide Amylin Receptor Agonist, And ASC36_35 FDC Once-Monthly Injection, A Co-Formulation Of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 7/5/2026

    Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today recent submissions of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for ASC36, a once-monthly to once-quarterly next-generation peptide amylin receptor agonist and ASC36_35 FDC, a once-monthly injection co-formulation of ASC36 plus peptide GLP-1R/GIPR agonist ASC35, for the treatment of obesity.

  10. INTENT Biologics Receives FDA Breakthrough Therapy Designation For PEP Biologic For Its Phase 3 Ready Flagship Indication 7/1/2026

    INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PEP Biologic for the treatment of diabetic foot ulcers (DFU) under IND 019567.